MetaVia announces research collaboration with Syntekabio

MetaVia (MTVA) announced a research collaboration with Syntekabio, a leading artificial intelligence-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia’s novel oral G-Protein-Coupled Receptor 119 agonist. This collaboration follows positive results from MetaVia’s 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis, or MASH, patients.